Pliant Therapeutics, Inc. (PLRX) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential
Current Price
$1.13
Price Target
—
Target Range
— — —
Analyst Rating
—
Forward P/E—
Trailing P/E-0.5x
Forward PEG—
Implied Growth—
Median Target—
Analyst Spread—
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$—
—
Consensus
$—
—
Bull Case
$—
—
PLRX Price Target Analysis
Updated June 13, 2026As of June 13, 2026, Pliant Therapeutics, Inc. (PLRX) has a Wall Street consensus price target of N/A, based on estimates from 0 covering analysts. The company has a market capitalization of $70M.
Analyst price targets range from a low of N/A to a high of N/A.
The current analyst consensus rating is N/A, with 0 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. The bearish sentiment suggests caution about the stock at current levels.
From a valuation perspective, PLRX trades at a trailing P/E of -0.5x.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+84.2%
Avg Forward P/E7.5x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 GILDGilead Sciences, Inc. | $155.9B | $125.59 | $161.12 | +28.3% | Buy | — | 58 |
 IDYAIDEAYA Biosciences, Inc. | $2.5B | $28.98 | $58.67 | +102.5% | Buy | — | 25 |
 HALOHalozyme Therapeutics, Inc. | $8.2B | $69.50 | $88.25 | +27.0% | Buy | 8.6x | 27 |
 AKBAAkebia Therapeutics, Inc. | $248M | $0.92 | $4.00 | +332.7% | Buy | — | 11 |
 INVAInnoviva, Inc. | $1.7B | $22.74 | $40.00 | +75.9% | Buy | 6.4x | 10 |
 MDGLMadrigal Pharmaceuticals, Inc. | $11.1B | $480.77 | $710.22 | +47.7% | Buy | — | 23 |
 AKROAkero Therapeutics, Inc. | $4.5B | $54.65 | $48.40 | -11.4% | Buy | — | 14 |
 HIMSHims & Hers Health, Inc. | $5.9B | $26.82 | $27.00 | +0.7% | Hold | — | 20 |
 ARWRArrowhead Pharmaceuticals, Inc. | $10.5B | $74.52 | $84.00 | +12.7% | Buy | — | 20 |
 VKTXViking Therapeutics, Inc. | $3.3B | $28.75 | $93.60 | +225.6% | Buy | — | 24 |
Upside Potential Comparison
AKBAVKTXIDYAINVAMDGLGILDHALOARWRWhat if you invested $1,000 in PLRX 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in PLRX be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs PLRX Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationPLRX vs LLY — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.
Compare NowPLRX — Frequently Asked Questions
Quick answers to the most common questions about buying PLRX stock.
What is the PLRX stock price target for 2026?
The consensus price target for PLRX is $N/A, close to the current price of $1.13 (N/A% implied move). Based on 0 analyst estimates, the stock appears fairly valued near current levels.
Is PLRX a buy, sell, or hold?
PLRX has a consensus rating of "N/A" based on 0 Wall Street analysts. The rating breakdown is mixed, with 0 Hold ratings making up the largest segment. The consensus 12-month price target of $N/A implies N/A% upside from current levels.
Is PLRX stock overvalued or undervalued?
PLRX's current price is $1.13 with a consensus target of $N/A (N/A% implied move). Analyst estimates suggest the stock is fairly valued at current levels.
How high can PLRX stock go?
The most bullish Wall Street analyst has a price target of $N/A for PLRX, while the most conservative target is $N/A. The consensus of $N/A represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover PLRX stock?
PLRX is lightly followed, with 0 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 0 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the PLRX stock forecast?
The 12-month PLRX stock forecast based on 0 Wall Street analysts shows a consensus price target of $N/A, with estimates ranging from $N/A (bear case) to $N/A (bull case). The median consensus rating is "N/A".
Should I buy PLRX stock?
PLRX appears fairly valued according to analysts, with a "N/A" rating and minimal upside to the $N/A target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do PLRX price targets vary so much?
PLRX analyst price targets range from $N/A to $N/A, a NaN% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $N/A consensus represents the middle ground.